Business
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. DALLAS--(BUSINESS WIRE)-- Lantern Pharma
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nWebcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. \n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.\n\n\nManagement intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2025 and provide guidance on upcoming milestones, clinical trials and developments of the AI platform, RADR®. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.\n\n\nTo register for the webinar, please sign up at the Zoom webcast link provided in the link: Lantern Pharma Q4 2025 earnings Zoom webcast registration link. A replay of the earnings call webcast will be available after the call on the investor relations section of the Company's website: ir.lanternpharma.com.\n\n\nAbout Lantern Pharma\n\n\nLantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its proprietary RADR® platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development timelines, and improve patient outcomes.\n\n\nFor more information, visit:\n\n\n\nWebsite: www.lanternpharma.com\n\n\n\nLinkedIn: https://www.linkedin.com/company/lanternpharma/\n\n\n\nX: @lanternpharma\n\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a dru...